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ABSTRACT
All heart muscle diseases that cause chronic
heart failure finally converge into one dreaded
pathological process that is myocardial fibrosis.
Myocardial fibrosis predicts major adverse car-
diovascular events and death, yet we are still
missing the targeted therapies capable of halt-
ing and/or reversing its progression. Funda-
mentally it is a problem of disproportionate
extracellular collagen accumulation that is part
of normal myocardial ageing and accentuated
in certain disease states. In this article we dis-
cuss the role of cardiovascular magnetic reso-
nance (CMR) imaging biomarkers to track
fibrosis and collate results from the most
promising animal and human trials of anti-fi-
brotic therapies to date. We underscore the
ever-growing role of CMR in determining the
efficacy of such drugs and encourage future
trialists to turn to CMR when designing their
surrogate study endpoints.
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Key Summary Points
Myocardial fibrosis is the shared final
common pathological pathway in the
development of chronic heart failure and
it predicts poor prognosis.
Myocardial fibrosis results from the
accumulation of collagen in the
extracellular matrix, mediated by the
complex interplay between pro-fibrotic
cells, growth factors and inflammatory
cytokines.
Various proposed anti-fibrotic drugs have
been tested but their direct beneficial
effects on human myocardial fibrosis are
yet to be proven.
CMR techniques like native T1 mapping
and extracellular volume have become the
gold standard non-invasive imaging
biomarkers of myocardial fibrosis.
Newer technologies in CMR are paving the
way for large-scale, multicentre,
randomised trials to determine the
efficacy of newer anti-fibrotic therapies.
INTRODUCTION
Disruption of the interstitial extracellular
matrix (ECM) has an important role in the
adverse myocardial remodelling that leads to
systolic and/or diastolic dysfunction and the
eventual development of chronic heart failure
[1, 2]. Myocardial fibrosis is characterised by the
disproportionate accumulation of collagen in
the ECM and it can be focal (following an acute
ischaemic event) or diffuse (in non-ischaemic
cardiomyopathy) [3]. Its presence is an impor-
tant prognostic marker in the development of
adverse cardiovascular events such as acute
heart failure, malignant arrhythmia and death.
There are three types of myocardial fibrosis:
(1) replacement fibrosis induced by cardiomy-
ocyte injury and death, as seen post myocardial
infarction; (2) reactive fibrosis which is the
gradual and reversible diffuse distribution of
excess collagen in the ECM like that observed in
non-ischaemic cardiomyopathy (Fig. 1a),
valvular heart disease and normal ageing [4]; (3)
infiltrative fibrosis that is secondary to the
accumulation (in ECM or in myocytes) of non-
collagenous materials such as amyloid (in car-
diac amyloidosis), iron (in haemochromatosis)
or glycosphingolipids (in Fabry disease, Fig. 1b)
[5].
A number of mediators have emerged as
potential targets for anti-fibrotic therapies but
most studies to determine their benefit are
based on animal models with mixed results
from human studies.
Our understanding of the mechanisms of
cardiac fibrosis has improved greatly in recent
years allowing us to refine non-invasive imag-
ing techniques to better track its development
and CMR is at the forefront of these innovations
[6].
This review explains how myocardial fibrosis
develops and how it can be non-invasively
detected and measured using CMR imaging. We
summarise findings from selected animal and
human trials of some of the more promising
targeted anti-fibrotic therapies and re-examine
the potential future role of CMR in such trials.
This review is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
PATHOPHYSIOLOGY
OF MYOCARDIAL FIBROSIS
The pathophysiological mechanisms of
myocardial fibrosis have been discussed else-
where [1]. Broadly speaking, the fibrotic
response involves a complex interplay between
circulating pro-fibrotic cell types, growth fac-
tors, hormones and pro-inflammatory cytoki-
nes, which is summarised in Fig. 2.
Cardiomyocyte call death (apoptosis) can result
from either a primary cardiac insult (e.g.
ischaemia) or in the context of systemic disease
(e.g. hypertension or chronic kidney disease)
[2]. Apoptosis can result in fibroblast
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proliferation through direct or indirect activa-
tion. Direct activation is facilitated by cell sig-
nalling proteins e.g. microRNAs (miRNAs) [7]
and matrix metalloproteinases (MMPs) [8].
Indirect activation is via circulating pro-fibrotic
mediators such as endothelial, epithelial and
inflammatory cells. Cardiac fibroblasts are the
cellular precursors of myofibroblasts which are
formed through a process of differentiation that
is driven by multiple growth factors and pro-
inflammatory cytokines, such as connective
tissue growth factor (CTGF) [9], tissue growth
factor-b (TGFb) and tumour necrosis factor-a
(TNFa) [1]. Renin–angiotensin–aldosterone sys-
tem (RAAS) activation is also thought to play an
important role [10] as well as newer mediators
such as galectin-3 (Gal-3) [11], endothelin [12]
and interleukin-11 (IL-11) [13]. The final com-
mon pathway of cardiac fibrosis is the deposi-
tion of collagen (from myofibroblasts) in the
ECM and histologically it can be quantified as
the collagen volume fraction (CVF), which is
Fig. 1 The value of CMR tissue characterisation in
distinguishing the underlying cause for LVH phenotypes.
Panel a shows a patient with familial HCM caused by a
pathogenicMYBPC3 mutation. There is asymmetric septal
hypertrophy and extensive diffuse and patchy LGE in the
hypertrophied segments with corresponding high native
myocardial T1 in these areas of fibrosis. Panel b shows a
male patient with LVH secondary to myocardial glycosph-
ingolipid accumulation in Fabry disease as a result of which
myocardial T1 times are low and there is the classic patch
of subepicardial fibrosis in the inferolateral wall. b/m/
aSAX basal/mid/apical short axis, 4/2C 4/2-chamber,
HCM hypertrophic cardiomyopathy, LGE late gadolinium
enhancement, LVH left ventricular hypertrophy, MOCO
motion-corrected, MOLLI modified Look-Locker inver-
sion recovery, MYBPC3 myosin-binding protein C3, PSIR
phase-sensitive inversion recovery, ShMOLLI shortened
MOLLI, SSFP steady-state free precession
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the proportion of collagen in the myocardium
compared to the volume of the myocardial
interstitium [14]. Our understanding of these
mechanisms has allowed us to develop poten-
tial therapeutic options which target the various
components of the pathway, from basic science
to animal and translational human trials.
CMR BIOMARKERS
OF MYOCARDIAL FIBROSIS
Native T1
T1 mapping in CMR [15] measures the T1
relaxation time of the myocardium. The native
T1 time, before the administration of
gadolinium-based contrast agents (GBCA),
lengthens because of the expansion of the
interstitial space arising from infarction,
oedema, fibrosis or infiltration and shortens
with accumulation of fat or iron [15]. The late
gadolinium enhancement (LGE) and extracel-
lular volume (ECV) techniques also measure
related readouts of the myocardial T1 but after
the administration of GBCA.
Native T1 mapping can be used to detect
areas of diffuse or focal myocardial fibrosis
without the need for any GBCA administration,
which can be particularly useful in patients in
whom the use of gadolinium is contraindicated.
The native myocardial T1 time predicts chronic
heart failure, arrhythmia and death [16] and
lengthens in the presence of frank myocardial
Fig. 2 Schema representing the development of myocar-
dial fibrosis and sites of action of potential therapeutic
targets. RAAS renin–angiotensin–aldosterone system,
TGFb tissue growth factor-b, TNFa tumour necrosis
factor-a, CTGF connective tissue growth factor, IL-11
interleukin-11, miRNA microRNA, MMP matrix metal-
loproteinases, Gal-3 galectin-3
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scarring (areas of LGE [10]). However, it can also
lengthen in the absence of (resolvable) LGE, for
example in dilated cardiomyopathy [17],
hypertrophic cardiomyopathy (HCM) [18] or
severe aortic stenosis [19] indicating more dif-
fuse myocardial fibrosis. The ability to detect
this so-called preclinical fibrosis (i.e. before vis-
ible LGE appears) is attractive because it means
that T1 can serve as a surrogate endpoint in
trials of novel anti-fibrotic therapies including
the effects on early phenotypes to prevent
chronic, irreversible heart failure.
Research into T1 mapping is ongoing with
the aim of improving accuracy and overcoming
challenges in acquisition and processing times
[15]. For example, motion artefacts are being
addressed with free-breathing and single breath-
hold sequences, and with whole heart T1 map-
ping techniques [20, 21]. Similar innovations
are also being used in patients with arrhythmia,
particularly atrial fibrillation [22]. Dark-blood
T1 mapping has been developed to clean the
myocardial signal from the partial volume
effects of the blood pool at the blood–myocar-
dial interface which enables parametric map-
ping of thin-walled structures and improves
data quality towards the apex [23, 24]. Post-
processing innovations and computer recon-
structions continue to improve the accuracy of
T1 measurements [25]. Dedicated T1 mapping
phantoms have been developed by our group to
aid in quality assurance (QA) and bring into line
the CMR data across multiple sites each oper-
ating different software and mapping sequences
[26]. Such QA infrastructure opens up the pos-
sibility for collaborative multicentre trials in
rare heart muscle diseases that are urgently
needed to upscale the currently limited studies
of anti-fibrotic therapies.
Late Gadolinium Enhancement
LGE corresponds to an area of focal scar (focal
fibrosis) in the myocardium and its presence is
associated with poor long-term cardiovascular
outcomes, including sudden cardiac death [27].
In previous studies myocardial biopsy of LGE
areas in patients with dilated cardiomyopathy
[28], myocarditis [29] and hypertrophic
cardiomyopathy [27] revealed both inflamma-
tion and fibrosis. One caveat of relying on the
sole LGE biomarker as a drug-trial surrogate
endpoint is its inability to detect diffuse fibrosis,
meaning that subtle improvements with ther-
apy will be missed. Another caveat is that the
evolution of new LGE foci, even in advanced
disease states, is an indolent process which
requires a certain threshold of conglomerated
myocardial cell death to be detectable using
modern-day CMR technologies. It means that
study follow-up to detect significant serial
change in LGE mass would have to be exceed-
ingly long (and costly).
Extracellular Volume
The redistribution of water and collagen into
the extracellular space that occurs with
myocardial fibrosis can be quantified by mea-
suring the myocardial T1 time before and after
GBCA administration and adjusting for blood
haematocrit, yielding the ECV [30]. ECV has
been shown to correlate with the amount of
collagen deposition on myocardial biopsy in
patients with various forms of cardiomyopathy
[31, 32]. ECV measurements are technically
limited in that they are most accurate in the
midwall and may therefore miss myocardial
fibrosis in the subendocardial and subepicardial
layers [1]. ECV’s correlation with fibrosis is
dependent on the absence of oedema or infil-
tration [30] and can be overestimated in the
presence of capillary vasodilation [15]. Despite
these potential drawbacks, a high myocardial
ECV has been consistently demonstrated in
patients with heart muscle disease [19, 33] and
shown to predict poor outcome [30], sometimes
better than LGE [30]. Interestingly in HCM,
myocardial ECV was also shown to be increased
in asymptomatic, mutation-positive relatives of
HCM probands [18] in whom there was no
detectable LGE. Similar to native T1 therefore,
ECV is lucrative biomarker of ‘subclinical’
fibrosis and another ideal therapeutic target for
anti-fibrotic therapies.
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T2 Mapping
T2 mapping, though not directly measuring
fibrosis, does provide insight into closely affili-
ated biological processes, namely myocardial
inflammation and oedema [34]. It does so
without the disadvantages of conventional T2-
weighted techniques [6]. Magnetic resonance
fingerprinting is an emerging technique which
allows for simultaneous T1 and T2 pixelwise
maps to be acquired in the same breathhold
[35]. This has the advantage of reducing scan
time whilst improving the reproducibility
because it allows for precise spatial correlation
of T1 and T2 mapping values per voxel, for a
more complete understanding of the interac-
tion between myocardial inflammation and
fibrosis [36]. It could prove to be a powerful tool
in future trials testing the usefulness of anti-fi-
brotic therapies.
TARGETED ANTI-FIBROTIC
THERAPIES
In this next part of the review we collate results
from the most promising animal and human
trials of anti-fibrotic therapies to date and
highlight some of the opportunities but also the
challenges of future clinical roll-out to patient
care.
Connective Tissue Growth Factor
Antagonists
CTGF is a matricellular protein which modu-
lates the cell signalling pathways responsible for
myofibroblast activation which underpins the
pathogenesis of fibrosis [9]. CTGF antagonists
may represent a novel strategy to limit and
reverse cardiac fibrosis. In one study, mice with
pressure overload-induced heart failure treated
with CTGF monoclonal antibodies (FG-3019)
showed a significant improvement in left ven-
tricular function when compared to controls
[37].
Galectin-3 Inhibitors
Gal-3 is a soluble beta-galactoside-binding lec-
tin and has recently emerged as a promising
biological target in heart failure as it mediates
cardiac fibroblast proliferation resulting in
fibrosis [38]. Multiple studies have shown that
Gal-3 is upregulated in hypertrophied hearts
[39–41], interstitial pneumonitis [42] and in the
plasma of patients with heart failure [11]. In one
study it was found that left ventricular hyper-
trophy was prevented in Gal-3 knockout mice
and that left ventricular function was amelio-
rated [43]. Gal-3 knockout in hypertensive mice
exposed to aldosterone led to reduced vascular
inflammation and hypertrophy compared to
controls [40]. Thus Gal-3 may serve not only as
an important clinical biomarker of heart failure
but also as a therapeutic target capable of
slowing the progression of cardiac fibrosis [11].
Anti-MicroRNAs
MiRNAs are members of a class of non-coding
RNAs expressed by cardiac myocytes which
regulate signalling pathways in fibroblasts.
Silencing miRNas in vivo has been shown to
prevent interstitial fibrosis and inhibit cardiac
function in pressure-overloaded mouse hearts
[7]. In another animal model, silencing the long
noncoding RNA (IncRNA) maternally expressed
gene 3 (Meg3) following aortic constriction
resulted in reduced myocyte fibrosis and
improved diastolic function [44]. Proteomics
comparison studies have also shown that rat
cardiac fibroblasts transfected with anti-miRNA
(pre-miR-29b) lost their ability to stick to myo-
cytes. It is this modulatory effect on the ECM
that has made miRNAs a tractable target for
therapeutic intervention but further work is
needed to improve our understanding of their
complex role in facilitating cardiac fibrosis [45].
Renin–Angiotensin–Aldosterone System
Inhibitors
RAAS inhibitors were amongst the first drugs
used to target cardiac fibrosis and many studies
proved their benefit independent of their
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antihypertensive effects. In a study of 34
patients with hypertension, endomyocardial
biopsies showed a reduction in left ventricular
chamber stiffness and fibrosis in those patients
treated with losartan [46]. Another biopsy study
found that lisinopril reduced CVF in car-
diomyocytes when compared to
hydrochlorothiazide [47]. Similar results were
obtained when comparing losartan with
amlodipine in patients with end-stage renal
disease [10] and hypertension [48]. The anti-fi-
brotic effect of RAAS inhibitors has been verified
by CMR in a cohort of losartan-treated patients
with HCM where a significant reduction in LGE
was observed [49]. Mineralocorticoid receptor
antagonists (MRAs) share a similar anti-fibrotic
effect. Circulating levels of fibrosis biomarkers
procollagen type 1 carboxy-terminal propeptide
(PICP) and procollagen-N-peptide (PINP) have
been used to study the effects of MRAs on car-
diac fibrosis in humans. Spironolactone reduced
PICP and PINP levels in 80 patients with meta-
bolic syndrome whilst improving left ventricu-
lar diastolic function [50]. Similar data emerged
for eplerenone in patients with heart failure
with preserved ejection fraction [51] and dias-
tolic dysfunction [52].
Nevertheless, in clinical practice patients
with heart failure on optimal medical therapy
that includes RAAS inhibitors continue to have
poor outcomes attributable to cardiac fibrosis,
suggesting that more work is needed to eluci-
date their anti-fibrotic benefits independent of
any combined antihypertensive and haemody-
namic effects.
Tissue Growth Factor-b Inhibitors
TGFb is a powerful profibrotic cytokine with an
active role in cardiac fibrosis. TGFb inhibitors
have been shown to reduce ECM protein syn-
thesis and fibrosis in pressure-overloaded mouse
hearts but the downside was increased mortality
and inflammation [53] which has limited their
clinical translation.
Pirfenidone (PFD) is an anti-fibrotic drug
which reduces the synthesis and release of TGFb
[54], thus reducing collagen deposition in both
lungs and kidneys [55]. In one murine study it
was also found to slow the decline in left ven-
tricular dysfunction, resulting in less ventricular
arrhythmia [56]. Similar effects were reported
for cardiac stiffness [57], left ventricular hyper-
trophy [58] and cardiac fibrosis [59] in pressure-
overloaded animal models. PFD can, however,
cause gastrointestinal upset and liver dysfunc-
tion which may hamper its widespread use as a
targeted anti-fibrotic drug.
Tranilast (N-[3,4-dimethoxycinnamoyl]an-
thranilic acid), previously used to treat keloid
scars and dermopathies characterised by exces-
sive fibrosis, has been shown to reduce collagen
deposition and improve left ventricular systolic
and diastolic function [60] in a diabetic rat
model. Yet results from the Prevention of
Restenosis With Tranilast and Its Outcomes
(PRESTO) trial were negative for tranilast as the
drug failed to improve quantitative measures of
restenosis using intravascular ultrasound and
angiography whilst causing a range of adverse
effects [61]. Other anti-TGFb drugs are on the
horizon and they include compound FT011
which is showing promising results and
improved tolerability when compared to trani-
last [62].
Endothelin Inhibitors
Endothelin is thought to play an important role
in the pathophysiology of fibrosis, so endothe-
lin receptor blockade could potentially prevent
the fibrosis of heart failure. Indeed in animal
models, endothelin antagonists reduced cardiac
fibrosis and left ventricular hypertrophy, and
improved survival [12, 63] whilst in 36 patients
with heart failure, bosentan improved left and
right heart haemodynamics including vascular
resistance when compared to placebo [64].
However, a more recent trial using CMR to
measure left ventricular end-diastolic volumes
found that administration of enrasentan resul-
ted in adverse cardiac remodelling compared to
controls [63]. Similar disappointing results were
reported in a large double-blind, placebo-con-
trolled trial of darusentan based on CMR end-
points of remodelling in chronic heart failure
[65]. Taken together these data suggest that
endothelin blockers may not be the ideal anti-
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fibrotic molecules but more work is needed to
demonstrate this conclusively.
Matricellular Protein Antagonists
Non-structural MMPs are overexpressed follow-
ing myocardial damage and contribute to the
functioning of cardiac fibroblasts [66]. MMP
knockout in animal models improved left ven-
tricular end-diastolic pressure following aortic
constriction [8] and reduced collagen deposi-
tion following myocardial infarction [67]. It has
also been postulated that angiotensin convert-
ing enzyme inhibitors (ACEi) exhibit direct
MMP antagonism [68, 69] which could be an
important indicator of the targeted effects of
ACEi in fibrosis. Less promising results have
been reported in humans where MMP inhibi-
tion failed to resolve left ventricular remod-
elling in an echocardiographic study [70].
Similarly, MMP deletion in mice exacerbated
cardiac dysfunction following scar formation in
myocardial infarction which continues to raise
the question of the usefulness of MMP inhibi-
tors in clinical practice [71].
Relaxin
Relaxin is a vasodilator hormone which reduces
the synthesis of collagen in the ECM through a
variety of processes including the inhibition of
profibrotic factors such as TGFb [72]. In
numerous animal studies it has been shown to
reduce cardiac fibrosis in the setting of acute
myocardial infarction [73], diabetes [74] and
hypertension [75]. It also reduced the incidence
of atrial fibrillation by reducing collagen depo-
sition and reversing atrial fibrosis in rat hearts
[76]. In another animal model, however,
endogenous relaxin had no effect on cardiac
fibrosis or hypertrophy following an 8-week
period of simulated pressure overload [77].
Clinical trials have replicated these negative
findings with the Relaxin for the Treatment of
Acute Heart Failure (RELAX-AHF) international
double-blind, placebo-controlled trial showing
that treatment with serelaxin did not affect
hospital readmission rates in acute heart failure
[78]. A phase II randomised trial using
recombinant human relaxin in patients with
scleroderma also showed no improvement in
patient symptoms as reflected by skin thickness
scores [79]. This disparity of benefit between
animal and human trials highlights the need for
further research into the use of relaxin in real-
world cardiac settings, in particular chronic
heart failure.
Loop Diuretics
The loop diuretic torsemide was superior to
furosemide in improving plasma brain natri-
uretic peptide levels, left ventricular function
and mortality in heart failure [80]. A ran-
domised study of patients with chronic heart
failure found reduced levels of PICP and colla-
gen deposition in septal myocardial biopsies in
those receiving torsemide compared to fur-
osemide [81]. These findings were echoed in
another study showing a reduction in markers
of fibrosis and improved left ventricular stiff-
ness [82, 83]. The large multicentre randomised
Torasemide Prolonged Release Versus Fur-
osemide in Patients With Chronic Heart Failure
(TORAFIC) trial, however, found no significant
difference between torsemide and furosemide in
terms of circulating PICP levels [84], although
patients recruited to this study had milder heart
failure compared to those from previous studies
[80]. There have been no CMR trials to date
directly testing the myocardial impacts of tor-
semide in terms of fibrosis burden.
Anti-Inflammatory Drugs
Inflammation has a role to play in the devel-
opment of myocardial fibrosis so drugs with
direct and indirect inflammatory modulatory
effects have long been trialled for their use in
this setting. Rosuvastatin reduced myocardial
fibrosis and had a positive effect on left ven-
tricular remodelling in a hypertensive rate
model [85] but the results of recent human trials
have been disappointing. The drug failed to
improve clinical outcomes in patients with
heart failure in a large (n = 5011) placebo-con-
trolled trial [86] and these findings were echoed
in subsequent trials showing an overall neutral
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benefit [87, 88]. TNFa has also been studied as a
potential fibrotic target in heart failure but trials
have been surprisingly negative. The targeted
anticytokine drug etanercept failed to show any
clinical benefit in chronic heart failure in terms
of mortality and hospital admissions [89]. A
randomised study using infliximab, a selective
TNFa antagonist, failed to show any benefit and
actually increased hospitalization in patients
with moderate to severe heart failure [90].
Overall, inflammatory modulating drugs have
not yet been shown to have a promising effect
as targeted anti-fibrotic medication in heart
failure. There have been some promising data
emerging from a study that used peroxisome
proliferator-activated receptor (PPAR) in hyper-
tensive rats which showed a reduction in
fibrosis and diastolic dysfunction [91]. However,
the widespread use of PPAR agonists in cardio-
vascular disease continues to be limited by their
unfavourable safety profile [91].
Anti-Fibrotic Therapies on the Horizon
IL-11 is believed to play an important role in the
pro-fibrotic pathway, downstream of TGFb. It
has been shown to be positively correlated with
cardiac fibroblast number and ECM deposition
ultimately leading to the development of car-
diac dysfunction [92]. In mouse models, dele-
tion of the IL-11 receptor was protective against
the development of myocardial fibrosis and
anti-IL-11 antibodies negated the effects of
TGFb stimulation on atrial myofibroblasts. This
promising work is inspiring the development of
a new class of anti-fibrotic therapies without the
side effects of TGFb inhibition discussed previ-
ously [13].
ROLE OF CMR IN TRIALLING ANTI-
FIBROTIC THERAPIES
The problem with determining the efficacy of
anti-fibrotic therapies lies in proving causality
between fibrosis regression and improved out-
comes. The majority of the aforementioned
treatments effect multiple generic disease path-
ways so conclusively proving their specific anti-
fibrotic benefits is difficult. ECV may be espe-
cially helpful here: it has already been shown to
be strongly and independently associated with
poor outcomes in patients with systolic heart
failure and in those with heart failure and pre-
served ejection fraction [93]; it is a well-estab-
lished CMR technique available to most CMR
units globally; and it is non-invasive and quick,
making serial assessment affordable for drug
companies, and tolerable for most patients.
Importantly myocardial fibrosis burden as asses-
sed by ECV has also been shown to have a
dose–response relationship with hospitalisation
and death in heart failure independent of LGE
[94], suggesting it is tracking additional biology.
ECV may go some way to help establish the
causal link that is needed to energise anti-fibrotic
drug trials. This biomarker is already being
exploited in randomised control trials as a sur-
rogate endpoint [95, 96]. We call for more
phase 2 and phase 3 drug trials to rely on the
ever-growingarmamentariumofCMR sequences
for fibrosis, in an effort to improve the reliability
and cost-effectiveness of studies, and maximise
their translational impact.
CONCLUSIONS
Myocardial fibrosis is the final point of conver-
gence for all heart muscle diseases, ushering in
the development of heart failure and death.
Effective anti-fibrotic therapies are urgently
needed but clinical trials are proving expensive
and results frankly disappointing. CMR imaging
biomarkers, in particular ECV and native T1, are
fascinating periscopes into the myocardial
response to drug therapy yet they are under-
utilised by pharma. These CMR techniques are
so sensitive that they can detect subclinical
fibrosis, opening that all-important window of
early drug intervention, before the irreversible
devastation caused by fibrosis takes hold.
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